This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Roche gets antitrust objections in Belgian probe of cancer drugs

By Lewis Crofts ( March 17, 2025, 15:34 GMT | Insight) -- Roche Group is the target of formal antitrust charges by the Belgian competition authority over a strategy to hamper competitive tenders and share false information about rival biosimilar drugs. The substances at issue have already been investigated and sanctioned by the Romanian competition authority. Roche Group is the target of formal antitrust charges by the Belgian competition authority over alleged moves to delay the launch of two cancer treatments between 2017 and 2020....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections